Sort by
Keyphrases
Adjusted Odds Ratio
50%
Baseline Covariates
16%
Calprotectin
16%
Clinical Remission
33%
Clinical Response
33%
Clinical Trials
16%
Comparative Effectiveness
16%
Comparative Efficacy
100%
Crohn's Disease
100%
Fecal Calprotectin
16%
Induction Therapy
16%
Inflammatory Bowel Disease
16%
Infliximab
100%
Moderate to Severe
16%
Multivariate Logistic Regression
16%
Nave
100%
No Significant Difference
16%
Number of Patients
16%
Onset of Action
16%
Patient-level Data
16%
Propensity Score
16%
Propensity-matched Cohort
16%
Proportion Difference
16%
Randomized Controlled Trial
16%
Response Rate
16%
Sensitivity Analysis
16%
Speed of Onset
16%
Treatment Group
16%
Ustekinumab
100%
Medicine and Dentistry
Calgranulin
16%
Clinical Trial
16%
Crohn's Disease
100%
Faecal Calprotectin
16%
Inflammatory Bowel Disease
16%
Infliximab
100%
Logistic Regression Analysis
16%
Odds Ratio
50%
Patient with Crohn's Disease
16%
Post-Hoc Analysis
33%
Randomized Controlled Trial
16%
Treatment Group
16%
Ustekinumab
100%
Pharmacology, Toxicology and Pharmaceutical Science
Calgranulin
33%
Clinical Trial
16%
Crohn's Disease
100%
Inflammatory Bowel Disease
16%
Infliximab
100%
Randomized Controlled Trial
16%
Remission
33%
Treatment Group
16%
Ustekinumab
100%
Immunology and Microbiology
Crohn's Disease
100%
Inflammatory Bowel Disease
16%
Infliximab
100%
Ustekinumab
100%
Biochemistry, Genetics and Molecular Biology
Calgranulin
33%
Clinical Trial
16%
Infliximab
100%
Randomized Controlled Trial
16%
Ustekinumab
100%
Neuroscience
Calgranulin
33%
Inflammatory Bowel Disease
16%
Infliximab
100%
Randomized Controlled Trial
16%
Ustekinumab
100%